Occurrence of psychotic symptoms during treatment of ADHD with methylphenidate: Clinical significance and the need for further research

1.Ramstad E, Storebø OJ, Gerner T, Krogh HB, Holmskov M, Magnusson FL, et al. Hallucinations and other psychotic symptoms in response to methylphenidate in children and adolescents with attention-deficit/hyperactivity disorder: a Cochrane systematic review with meta-analysis and trial sequential analysis. Scand J Child and Adolesc Psychiatr and Psychol 2018;6:52-71.RamstadEStorebøOJGernerTKroghHBHolmskovMMagnussonFL, Hallucinations and other psychotic symptoms in response to methylphenidate in children and adolescents with attention-deficit/hyperactivity disorder: a Cochrane systematic review with meta-analysis and trial sequential analysis. Scand J Child and Adolesc Psychiatr and Psychol2018;6:52-71.10.21307/sjcapp-2018-003775070233520751Search in Google Scholar

2.Storebø OJ, Ramstad E, Krogh HB, Nilausen TD, Skoog M, Holmskov M, et al. Methyphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database Syst Rev 2015;1:CD009885.StorebøOJRamstadEKroghHBNilausenTDSkoogMHolmskovM, Methyphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database Syst Rev2015;1:CD009885.10.1002/14651858.CD009885.pub2876335126599576Search in Google Scholar

3.Storebø OJ, Pedersen N, Ramstad E, Kielsholm MI, Nielsen SS, Krogh HB et al. Methylpheidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents – assessment of possible adverse events in non-randomised studies. Cochrane Database Syst Rev 2018;5:CD012069.StorebøOJPedersenNRamstadEKielsholmMINielsenSSKroghHBMethylpheidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents – assessment of possible adverse events in non-randomised studies. Cochrane Database Syst Rev2018;5:CD012069.10.1002/14651858.CD012069.pub2649455429744873Search in Google Scholar

4.Reichenberg A, Caspi A, Harrington H, Houts R, Keefe RSE, Murray R, et al. Static and dynamic cognitive deficits in childhood preceding adult schizophrenia: A 30-year study. Am J Psychiatry 2010; 167:160-9.ReichenbergACaspiAHarringtonHHoutsRKeefeRSEMurrayR, Static and dynamic cognitive deficits in childhood preceding adult schizophrenia: A 30-year study. Am J Psychiatry2010; 167:160-9.10.1176/appi.ajp.2009.09040574355232520048021Search in Google Scholar

5.Ellersgaard D, Plessen KJ, Richardt JR, Spang KS, Hemanger N, Burton BK, et al. Psychopathology in 7-year-old children with familial high risk of developing schizophrenia spectrum psychosis or bipolar disorder – The Danish High Risk and Resilience Study – VIA 7, a population-based cohort study. World Psychiatry 2018:17:210-19.EllersgaardDPlessenKJRichardtJRSpangKSHemangerNBurtonBK, Psychopathology in 7-year-old children with familial high risk of developing schizophrenia spectrum psychosis or bipolar disorder – The Danish High Risk and Resilience Study – VIA 7, a population-based cohort study. World Psychiatry2018:17:210-19.10.1002/wps.20527598063329856544Search in Google Scholar

6.Larsson H, Rydén E, Boman M, Långström N, Lichtenstein P, Landén M. Risk of bipolar disorder and schizophrenia in relatives of people with attention-deficit hyperactivity disorder. Br J Psychiatry 2013; 203:103-6.LarssonHRydénEBomanMLångströmNLichtensteinPLandénM.Risk of bipolar disorder and schizophrenia in relatives of people with attention-deficit hyperactivity disorder. Br J Psychiatry2013; 203:103-6.10.1192/bjp.bp.112.120808373011323703314Search in Google Scholar

7.Nivard MG, Gage SH, Hottenga JJ, van Beijsterveldt CEM, Abdellaoui A, Bartels M, et al. Genetic overlap between schizophrenia and developmental psychopathology: Longitudinal and multivariate polygenic risk prediction of common psychiatric traits during development. Schizophr Bull 2017;43:1197-1207.NivardMGGageSHHottengaJJvan BeijsterveldtCEMAbdellaouiABartelsM, Genetic overlap between schizophrenia and developmental psychopathology: Longitudinal and multivariate polygenic risk prediction of common psychiatric traits during development. Schizophr Bull2017;43:1197-1207.10.1093/schbul/sbx031573769428338919Search in Google Scholar

8.Moran LV, Masters GA, Pingali S, Cohen BM, Liebson E, Rajarethinam RP, et al. Prescription stimulant use is associated with earlier onset of psychosis. J Psychiatr Res 2015;71:41-47.MoranLVMastersGAPingaliSCohenBMLiebsonERajarethinamRP, Prescription stimulant use is associated with earlier onset of psychosis. J Psychiatr Res2015;71:41-47.10.1016/j.jpsychires.2015.09.012463067226522870Search in Google Scholar

9.Myer NM, Boland JR, Faraone SV. Pharmacogentics predictors of methylphenidate efficacy in childhood ADHD. Mol Psychiatry 2017 Dec 12 [Epub ahead of print]. https://doi.org/10.1038/mp.2017.234MyerNMBolandJRFaraoneSV.Pharmacogentics predictors of methylphenidate efficacy in childhood ADHD. Mol Psychiatry2017Dec12 [Epub ahead of print]. https://doi.org/10.1038/mp.2017.23410.1038/mp.2017.234703966329230023Search in Google Scholar